Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
15.66
-0.18 (-1.14%)
At close: May 29, 2025, 4:00 PM
15.64
-0.02 (-0.13%)
After-hours: May 29, 2025, 6:19 PM EDT

Mineralys Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-188.51-177.81-71.9-29.8-19.41-3.43
Depreciation & Amortization
0.050.04----
Loss (Gain) From Sale of Investments
-7.94-9.41-6.87-0.65--
Stock-Based Compensation
12.7911.345.060.460.080
Other Operating Activities
----0.680.48
Change in Accounts Payable
-5.784.162.423.014.470.54
Change in Other Net Operating Assets
-3.265.36-9.89-2.24-0.39-0.06
Operating Cash Flow
-192.66-166.31-81.17-29.22-14.56-2.46
Capital Expenditures
-0.04-0.1----
Investment in Securities
78.07115.06-160.47-21.76--
Investing Cash Flow
78.04114.96-160.47-21.76--
Short-Term Debt Issued
-----3.85
Total Debt Issued
-----3.85
Net Debt Issued (Repaid)
-----3.85
Issuance of Common Stock
189.6116.58203.25---
Other Financing Activities
-0.38-0.44--1.63--0.02
Financing Cash Flow
189.22116.14203.25128.0223.813.83
Net Cash Flow
74.5964.79-38.477.049.251.37
Free Cash Flow
-192.7-166.41-81.17-29.22-14.56-2.46
Free Cash Flow Per Share
-3.81-3.43-2.24-5.66-2.92-0.53
Levered Free Cash Flow
-122.17-99.43-55.27-18.4-7.62-
Unlevered Free Cash Flow
-122.17-99.43-55.27-18.4-7.61-
Change in Net Working Capital
9.04-9.547.42-0.82-4.02-
Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q